Expression of interleukin-10 splicing variants is a positive prognostic feature in relapsed childhood acute lymphoblastic leukemia

Biologic features of hematologic malignancies have prognostic implications and are essential elements in the design of current therapeutic trials. This study aimed to determine the expression of a splicing-derived variant of interleukin (IL) -10 in leukemic cells and its clinical relevance in childr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical oncology Vol. 23; no. 13; p. 3038
Main Authors: Wu, Shuling, Gessner, Reinhard, Taube, Tillmann, von Stackelberg, Arend, Henze, Günter, Seeger, Karl
Format: Journal Article
Language:English
Published: United States 01.05.2005
Subjects:
Adolescent
Alternative Splicing
Child
Child, Preschool
Female
Gene Expression Profiling
Genetic Variation
Humans
Immunoblotting
Infant
Interleukin-10 - genetics
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology
Prognosis
Recurrence
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Treatment Outcome
ISSN:0732-183X
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Biologic features of hematologic malignancies have prognostic implications and are essential elements in the design of current therapeutic trials. This study aimed to determine the expression of a splicing-derived variant of interleukin (IL) -10 in leukemic cells and its clinical relevance in children with acute lymphoblastic leukemia (ALL) at first relapse. Between January 1997 and December 2001, bone marrow (BM) samples were collected from 98 children with first relapse of ALL at diagnosis. These patients were enrolled in the relapse trial ALL-REZ BFM (ALL-Relapse Berlin-Frankfurt-Munster) 95 and 96. The detection of IL-10 isoforms in leukemic cells of BM samples were performed by conventional reverse transcriptase polymerase chain reaction and by immunoblotting. IL-10 was detected in 93.9% BM samples. In addition to expressing full-length IL-10, a new splicing-derived IL-10 variant (termed IL-10delta3) that lacked the entire exon 3 was identified in leukemic cells. The IL-10delta3 variant was found in 80.4% of BM samples. Most importantly, expression of IL-10delta3 was associated with a significantly better response to chemotherapy (P = .001) and probability of event-free survival (P = .01) at 5 years. These results indicate that splicing-derived IL-10 isoforms may modulate IL-10-mediated biologic effects and therapeutic efficacy in lymphatic disease, and expression of IL-10delta3 is a positive prognostic feature in relapsed childhood ALL.
AbstractList Biologic features of hematologic malignancies have prognostic implications and are essential elements in the design of current therapeutic trials. This study aimed to determine the expression of a splicing-derived variant of interleukin (IL) -10 in leukemic cells and its clinical relevance in children with acute lymphoblastic leukemia (ALL) at first relapse.PURPOSEBiologic features of hematologic malignancies have prognostic implications and are essential elements in the design of current therapeutic trials. This study aimed to determine the expression of a splicing-derived variant of interleukin (IL) -10 in leukemic cells and its clinical relevance in children with acute lymphoblastic leukemia (ALL) at first relapse.Between January 1997 and December 2001, bone marrow (BM) samples were collected from 98 children with first relapse of ALL at diagnosis. These patients were enrolled in the relapse trial ALL-REZ BFM (ALL-Relapse Berlin-Frankfurt-Munster) 95 and 96. The detection of IL-10 isoforms in leukemic cells of BM samples were performed by conventional reverse transcriptase polymerase chain reaction and by immunoblotting.PATIENTS AND METHODSBetween January 1997 and December 2001, bone marrow (BM) samples were collected from 98 children with first relapse of ALL at diagnosis. These patients were enrolled in the relapse trial ALL-REZ BFM (ALL-Relapse Berlin-Frankfurt-Munster) 95 and 96. The detection of IL-10 isoforms in leukemic cells of BM samples were performed by conventional reverse transcriptase polymerase chain reaction and by immunoblotting.IL-10 was detected in 93.9% BM samples. In addition to expressing full-length IL-10, a new splicing-derived IL-10 variant (termed IL-10delta3) that lacked the entire exon 3 was identified in leukemic cells. The IL-10delta3 variant was found in 80.4% of BM samples. Most importantly, expression of IL-10delta3 was associated with a significantly better response to chemotherapy (P = .001) and probability of event-free survival (P = .01) at 5 years.RESULTSIL-10 was detected in 93.9% BM samples. In addition to expressing full-length IL-10, a new splicing-derived IL-10 variant (termed IL-10delta3) that lacked the entire exon 3 was identified in leukemic cells. The IL-10delta3 variant was found in 80.4% of BM samples. Most importantly, expression of IL-10delta3 was associated with a significantly better response to chemotherapy (P = .001) and probability of event-free survival (P = .01) at 5 years.These results indicate that splicing-derived IL-10 isoforms may modulate IL-10-mediated biologic effects and therapeutic efficacy in lymphatic disease, and expression of IL-10delta3 is a positive prognostic feature in relapsed childhood ALL.CONCLUSIONThese results indicate that splicing-derived IL-10 isoforms may modulate IL-10-mediated biologic effects and therapeutic efficacy in lymphatic disease, and expression of IL-10delta3 is a positive prognostic feature in relapsed childhood ALL.
Biologic features of hematologic malignancies have prognostic implications and are essential elements in the design of current therapeutic trials. This study aimed to determine the expression of a splicing-derived variant of interleukin (IL) -10 in leukemic cells and its clinical relevance in children with acute lymphoblastic leukemia (ALL) at first relapse. Between January 1997 and December 2001, bone marrow (BM) samples were collected from 98 children with first relapse of ALL at diagnosis. These patients were enrolled in the relapse trial ALL-REZ BFM (ALL-Relapse Berlin-Frankfurt-Munster) 95 and 96. The detection of IL-10 isoforms in leukemic cells of BM samples were performed by conventional reverse transcriptase polymerase chain reaction and by immunoblotting. IL-10 was detected in 93.9% BM samples. In addition to expressing full-length IL-10, a new splicing-derived IL-10 variant (termed IL-10delta3) that lacked the entire exon 3 was identified in leukemic cells. The IL-10delta3 variant was found in 80.4% of BM samples. Most importantly, expression of IL-10delta3 was associated with a significantly better response to chemotherapy (P = .001) and probability of event-free survival (P = .01) at 5 years. These results indicate that splicing-derived IL-10 isoforms may modulate IL-10-mediated biologic effects and therapeutic efficacy in lymphatic disease, and expression of IL-10delta3 is a positive prognostic feature in relapsed childhood ALL.
Author Gessner, Reinhard
Henze, Günter
Seeger, Karl
Taube, Tillmann
von Stackelberg, Arend
Wu, Shuling
Author_xml – sequence: 1
  givenname: Shuling
  surname: Wu
  fullname: Wu, Shuling
  email: shuling.wu@charite.de
  organization: Institute of Laboratory Medicine and Pathobiochemistry, Charité Medical Center, Humboldt University Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. shuling.wu@charite.de
– sequence: 2
  givenname: Reinhard
  surname: Gessner
  fullname: Gessner, Reinhard
– sequence: 3
  givenname: Tillmann
  surname: Taube
  fullname: Taube, Tillmann
– sequence: 4
  givenname: Arend
  surname: von Stackelberg
  fullname: von Stackelberg, Arend
– sequence: 5
  givenname: Günter
  surname: Henze
  fullname: Henze, Günter
– sequence: 6
  givenname: Karl
  surname: Seeger
  fullname: Seeger, Karl
BackLink https://www.ncbi.nlm.nih.gov/pubmed/15860861$$D View this record in MEDLINE/PubMed
BookMark eNo1kLtPwzAYxD0U0QfMbMgTW4LtxIk7oqq8VKkLSGzRF-dLa3DsECcVXfnLCa_plrvfnW5OJs47JOSCs5gLxq4fV9t4VBkzFislJ2TG8kREXCUvUzIP4ZUxnqpEnpIplypjKuMz8rn-aDsMwXhHfU2N67GzOLwZF3FGQ2uNNm5HD9AZcH2gJlCgrQ-mNwekbed3zofeaFoj9EOHI4F2aKENWFG9N7bae19R0EOP1B6bdu9LCz-J7xpsDJyRkxpswPM_XZDn2_XT6j7abO8eVjebSCcy76NaQ1nLpGZlxfKlSrjMAaRApZdlIlIUmKaMLTOsIMl0xpjAGtJKlFxDzgHEglz9csfV7wOGvmhM0GgtOPRDKLJcjQ9JNRov_4xD2WBVtJ1poDsW_6-JL3eccm4
CitedBy_id crossref_primary_10_1158_0008_5472_CAN_08_0444
crossref_primary_10_1016_j_virusres_2007_09_011
crossref_primary_10_1038_s41598_017_03167_0
crossref_primary_10_1186_s13046_015_0179_9
crossref_primary_10_1007_s12032_013_0460_8
crossref_primary_10_1016_j_canlet_2012_12_003
crossref_primary_10_1038_s41598_019_40786_1
crossref_primary_10_1002_bies_20390
crossref_primary_10_1016_j_uct_2006_05_007
crossref_primary_10_3109_08830180903349651
crossref_primary_10_1016_j_cyto_2016_08_012
crossref_primary_10_1093_hmg_ddl147
crossref_primary_10_3389_fcimb_2020_558799
crossref_primary_10_1016_j_molimm_2015_06_022
crossref_primary_10_1186_s12885_024_12677_w
crossref_primary_10_1002_hon_730
crossref_primary_10_1016_j_cyto_2011_07_020
crossref_primary_10_1016_j_dci_2012_03_012
crossref_primary_10_1016_j_gene_2012_01_076
crossref_primary_10_1007_s12185_009_0393_3
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1200/JCO.2005.00.885
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 15860861
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.55
.GJ
08P
0R~
18M
2WC
34G
39C
3O-
4.4
53G
5GY
5RE
8F7
8WZ
A6W
AAKAS
AARDX
AAWTL
AAYEP
AAYOK
ABJNI
ABOCM
ACGFO
ACGFS
ACGUR
ADBBV
ADZCM
AEGXH
AENEX
AFFNX
AI.
AIAGR
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AWKKM
AZFZN
BAWUL
C45
CGR
CS3
CUY
CVF
DIK
EBS
ECM
EIF
EJD
F5P
F9R
FBNNL
FD8
GX1
H13
HZ~
IH2
KQ8
L7B
LSO
MJL
N4W
N9A
NPM
O9-
OK1
OVD
OWW
P2P
QTD
R1G
RHI
RLZ
RUC
SJN
SV3
TEORI
TR2
TWZ
UDS
VH1
VVN
WH7
X7M
YCJ
YFH
YQY
ZGI
7X8
ABBLC
ID FETCH-LOGICAL-c357t-fcabf53f0bd07983157aa52e8c9b324e2e440096eda36c6002efa4d2b1ca71aa2
IEDL.DBID 7X8
ISICitedReferencesCount 20
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000228817900024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0732-183X
IngestDate Thu Oct 02 05:32:16 EDT 2025
Sat Sep 28 07:44:24 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 13
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c357t-fcabf53f0bd07983157aa52e8c9b324e2e440096eda36c6002efa4d2b1ca71aa2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 15860861
PQID 67800158
PQPubID 23479
ParticipantIDs proquest_miscellaneous_67800158
pubmed_primary_15860861
PublicationCentury 2000
PublicationDate 2005-05-01
PublicationDateYYYYMMDD 2005-05-01
PublicationDate_xml – month: 05
  year: 2005
  text: 2005-05-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of clinical oncology
PublicationTitleAlternate J Clin Oncol
PublicationYear 2005
SSID ssj0014835
Score 1.8917562
Snippet Biologic features of hematologic malignancies have prognostic implications and are essential elements in the design of current therapeutic trials. This study...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 3038
SubjectTerms Adolescent
Alternative Splicing
Child
Child, Preschool
Female
Gene Expression Profiling
Genetic Variation
Humans
Immunoblotting
Infant
Interleukin-10 - genetics
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology
Prognosis
Recurrence
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Treatment Outcome
Title Expression of interleukin-10 splicing variants is a positive prognostic feature in relapsed childhood acute lymphoblastic leukemia
URI https://www.ncbi.nlm.nih.gov/pubmed/15860861
https://www.proquest.com/docview/67800158
Volume 23
WOSCitedRecordID wos000228817900024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9tAEB7SppRemjRt2iRNO4eSU5ZY2l2vDIFQQkIIjetDWnwzu6tdMEkkN7JNfe0vz4we-FR6KAgdJFYSzGgeO998A_DFeKMTI50wA-OEcj0rHKURwiQqoeyB7tRgzJ_fzHCYjceD0Qacdr0wDKvsbGJtqPPS8x75CRlV9u_Z2eyX4JlRXFttB2g8g01JgQwDusx4XUNQWTNe08hUkOKOW2IfUouT6_Pv3XYKaYr-e3RZe5nLrf_7vm143UaX-LVRhzewEYodeHnT1s934GjUMFWvjvF23XhVHeMRjtYc1qu38Ofid4uQLbCMyKQSj_dhcTctyKJixUVv8nm4pEybgTQ4rdBiAwBbBmTQV1EyAzTGUDOH0hOQ22ZmVcjRd3TKaP1iHvB-RSpVOorjeQW_JjxM7Tv4cXlxe34l2nENwktt5iJ666KWsefynhlkMtHGWp2GzA8chW0hDUpxxhRyK_ue64EhWpWnLvHWJNamu_C8KIvwAdBo7VJtVUaHkipzfSfzGHPvNIWbeW8PPndCmNDvwDUOW4RyUU06MezB-0aOk1nD2jGhi33K35L9f649gFc1QWsNa_wIm5EMQTiEF345n1aPn2oto_NwdPMElKLfVw
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expression+of+interleukin-10+splicing+variants+is+a+positive+prognostic+feature+in+relapsed+childhood+acute+lymphoblastic+leukemia&rft.jtitle=Journal+of+clinical+oncology&rft.au=Wu%2C+Shuling&rft.au=Gessner%2C+Reinhard&rft.au=Taube%2C+Tillmann&rft.au=von+Stackelberg%2C+Arend&rft.date=2005-05-01&rft.issn=0732-183X&rft.volume=23&rft.issue=13&rft.spage=3038&rft_id=info:doi/10.1200%2FJCO.2005.00.885&rft_id=info%3Apmid%2F15860861&rft_id=info%3Apmid%2F15860861&rft.externalDocID=15860861
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon